Genetron Health

Specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.

Launch date

2013

Employees

Market cap

Enterprise valuation

CAD140m (Public information from Mar 2024)

Beijing China (HQ)

http://www.genetronhealth.com/

https://www.linkedin.com/company/genetronhealth

Revenues, earnings & profits over time

CNY	2017	2018	2019	2020	2021	2022	2023
Revenues	109m	248m	323m	424m	532m	651m	765m
% growth	-	127 %	31 %	31 %	25 %	22 %	18 %
EBITDA	(431m)	(233m)	(626m)	(3.0b)	(460m)	(546m)	-
% EBITDA margin	(395 %)	(94 %)	(193 %)	(718 %)	(87 %)	(84 %)	-
Profit	(453m)	(512m)	(676m)	(3.1b)	(496m)	(808m)	-
% profit margin	(416 %)	(207 %)	(209 %)	(723 %)	(93 %)	(124 %)	-
R&D budget	49.3m	78.6m	91.7m	149m	254m	290m	-
R&D % of revenue	45 %	32 %	28 %	35 %	48 %	45 %	-

Date	Investors	Amount	Round
Sep 2015*	Origene Technologies Share Capital	CNY50.0m	Series A
Sep 2016	New Horizon Capital Zhongyuan Union Cell & Gene Eng Share Capital	N/A	Series B
Jan 2018	N/A	N/A	Series C
Nov 2019	Vivo Capital Alexandria Venture Investments Highlight Capital	$71.0m	Series D
Jun 2020	N/A	N/A	IPO
Total Funding		CAD106m

Tech stackLearn more about the technologies and tools that this company uses.

Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC.

Genetron New Co

ACQUISITION by Genetron Health Oct 2023